Patient Advisory Council to include advocates from the inherited retinal diseases global community New Patient Advisory Council to focus initially on Company ’ s clinical stage programs for X-linked retinitis pigmentosa (XLRP) GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug.
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 15, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
- Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE, Fla. , and CAMBRIDGE, Mass.
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - GAINESVILLE, Fla.
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
